St. Jude Medical's Epic II devices for heart arrhythmias, failure, receive CE Mark approval

By Lisa Kerner

Charlotte, N.C., June 13 - St. Jude Medical, Inc. said it has received European CE Mark approval for its Epic II ICD (implantable cardioverter defibrillator) and Epic II HF CRT-D (cardiac resynchronization therapy defibrillator) for the treatment of heart arrhythmias and heart failure.

The devices feature faster data transmission to speed patient follow-up exams and a "patient notifier" that vibrates to alert patients of critical changes in device function, according to a company news release.

The Epic II devices received Food and Drug Administration approval in May.

"The Epic II devices offer important benefits to patients and their physicians, including an innovative patient notification feature, advanced diagnostics and the ability to conduct faster follow-up exams," executive vice president Eric S. Fain said in the release.

"These devices, along with the recently launched Merlin Patient Care System, provide state-of-the-art technology to European physicians as they manage the complexities of heart failure."

An ICD delivers potentially life-saving therapy to the patient's heart through an insulated wire or lead.

Cardiac resynchronization therapy is delivered in an ICD or a pacemaker.

Based in St. Paul, Minn., St. Jude Medical is focused on cardiac rhythm management, atrial fibrillation, cardiac surgery, cardiology and neuromodulation.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.